• Something wrong with this record ?

The Development of a Recombinant scFv Monoclonal Antibody Targeting Canine CD20 for Use in Comparative Medicine

S. Jain, L. Aresu, S. Comazzi, J. Shi, E. Worrall, J. Clayton, W. Humphries, S. Hemmington, P. Davis, E. Murray, AA. Limeneh, K. Ball, E. Ruckova, P. Muller, B. Vojtesek, R. Fahraeus, D. Argyle, TR. Hupp,

. 2016 ; 11 (2) : e0148366. [pub] 20160219

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16027656

Monoclonal antibodies are leading agents for therapeutic treatment of human diseases, but are limited in use by the paucity of clinically relevant models for validation. Sporadic canine tumours mimic the features of some human equivalents. Developing canine immunotherapeutics can be an approach for modeling human disease responses. Rituximab is a pioneering agent used to treat human hematological malignancies. Biologic mimics that target canine CD20 are just being developed by the biotechnology industry. Towards a comparative canine-human model system, we have developed a novel anti-CD20 monoclonal antibody (NCD1.2) that binds both human and canine CD20. NCD1.2 has a sub-nanomolar Kd as defined by an octet red binding assay. Using FACS, NCD1.2 binds to clinically derived canine cells including B-cells in peripheral blood and in different histotypes of B-cell lymphoma. Immunohistochemical staining of canine tissues indicates that the NCD1.2 binds to membrane localized cells in Diffuse Large B-cell lymphoma, Marginal Zone Lymphoma, and other canine B-cell lymphomas. We cloned the heavy and light chains of NCD1.2 from hybridomas to determine whether active scaffolds can be acquired as future biologics tools. The VH and VL genes from the hybridomas were cloned using degenerate primers and packaged as single chains (scFv) into a phage-display library. Surprisingly, we identified two scFv (scFv-3 and scFv-7) isolated from the hybridoma with bioactivity towards CD20. The two scFv had identical VH genes but different VL genes and identical CDR3s, indicating that at least two light chain mRNAs are encoded by NCD1.2 hybridoma cells. Both scFv-3 and scFv-7 were cloned into mammalian vectors for secretion in CHO cells and the antibodies were bioactive towards recombinant CD20 protein or peptide. The scFv-3 and scFv-7 were cloned into an ADEPT-CPG2 bioconjugate vector where bioactivity was retained when expressed in bacterial systems. These data identify a recombinant anti-CD20 scFv that might form a useful tool for evaluation in bioconjugate-directed anti-CD20 immunotherapies in comparative medicine.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16027656
003      
CZ-PrNML
005      
20161005132243.0
007      
ta
008      
161005s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0148366 $2 doi
024    7_
$a 10.1371/journal.pone.0148366 $2 doi
035    __
$a (PubMed)26894679
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jain, Saurabh $u University of Edinburgh, Institute of Genetic and Molecular Medicine and School of Veterinary Medicine, Edinburgh, EH4 2XR, United Kingdom.
245    14
$a The Development of a Recombinant scFv Monoclonal Antibody Targeting Canine CD20 for Use in Comparative Medicine / $c S. Jain, L. Aresu, S. Comazzi, J. Shi, E. Worrall, J. Clayton, W. Humphries, S. Hemmington, P. Davis, E. Murray, AA. Limeneh, K. Ball, E. Ruckova, P. Muller, B. Vojtesek, R. Fahraeus, D. Argyle, TR. Hupp,
520    9_
$a Monoclonal antibodies are leading agents for therapeutic treatment of human diseases, but are limited in use by the paucity of clinically relevant models for validation. Sporadic canine tumours mimic the features of some human equivalents. Developing canine immunotherapeutics can be an approach for modeling human disease responses. Rituximab is a pioneering agent used to treat human hematological malignancies. Biologic mimics that target canine CD20 are just being developed by the biotechnology industry. Towards a comparative canine-human model system, we have developed a novel anti-CD20 monoclonal antibody (NCD1.2) that binds both human and canine CD20. NCD1.2 has a sub-nanomolar Kd as defined by an octet red binding assay. Using FACS, NCD1.2 binds to clinically derived canine cells including B-cells in peripheral blood and in different histotypes of B-cell lymphoma. Immunohistochemical staining of canine tissues indicates that the NCD1.2 binds to membrane localized cells in Diffuse Large B-cell lymphoma, Marginal Zone Lymphoma, and other canine B-cell lymphomas. We cloned the heavy and light chains of NCD1.2 from hybridomas to determine whether active scaffolds can be acquired as future biologics tools. The VH and VL genes from the hybridomas were cloned using degenerate primers and packaged as single chains (scFv) into a phage-display library. Surprisingly, we identified two scFv (scFv-3 and scFv-7) isolated from the hybridoma with bioactivity towards CD20. The two scFv had identical VH genes but different VL genes and identical CDR3s, indicating that at least two light chain mRNAs are encoded by NCD1.2 hybridoma cells. Both scFv-3 and scFv-7 were cloned into mammalian vectors for secretion in CHO cells and the antibodies were bioactive towards recombinant CD20 protein or peptide. The scFv-3 and scFv-7 were cloned into an ADEPT-CPG2 bioconjugate vector where bioactivity was retained when expressed in bacterial systems. These data identify a recombinant anti-CD20 scFv that might form a useful tool for evaluation in bioconjugate-directed anti-CD20 immunotherapies in comparative medicine.
650    _2
$a sekvence aminokyselin $7 D000595
650    _2
$a zvířata $7 D000818
650    _2
$a tvorba protilátek $x imunologie $7 D000917
650    _2
$a specificita protilátek $x imunologie $7 D000918
650    12
$a antigeny CD20 $x chemie $x genetika $x imunologie $x metabolismus $7 D018951
650    _2
$a buněčné linie $7 D002460
650    _2
$a klonování DNA $7 D003001
650    _2
$a psi $7 D004285
650    _2
$a epitopy $x imunologie $7 D000939
650    _2
$a exprese genu $7 D015870
650    _2
$a lidé $7 D006801
650    _2
$a hybridomy $x imunologie $x metabolismus $7 D006825
650    _2
$a těžké řetězce imunoglobulinů $x genetika $7 D007143
650    _2
$a lehké řetězce imunoglobulinů $x genetika $7 D007147
650    _2
$a myši $7 D051379
650    _2
$a molekulární sekvence - údaje $7 D008969
650    _2
$a peptidová knihovna $7 D019151
650    _2
$a peptidy $x chemie $x metabolismus $7 D010455
650    _2
$a vazba proteinů $x imunologie $7 D011485
650    _2
$a rekombinantní fúzní proteiny $x farmakologie $7 D011993
650    _2
$a sekvenční seřazení $7 D016415
650    _2
$a jednořetězcové protilátky $x imunologie $x farmakologie $7 D057127
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Aresu, Luca $u Dipartimento di Biomedicina Comparata e Alimentazione (BCA) Department of Comparative Biomedicine and Food Science, Università di Padova 35020 Legnaro (PD), Italy. $7 gn_A_00008290
700    1_
$a Comazzi, Stefano $u Dipartimento di Scienze Veterinarie e Sanità Pubblica, Università degli Studi di Milano, via Celoria 10, 20133 Milano, Italy.
700    1_
$a Shi, Jianguo $u University of Edinburgh, Institute of Genetic and Molecular Medicine and School of Veterinary Medicine, Edinburgh, EH4 2XR, United Kingdom.
700    1_
$a Worrall, Erin $u University of Edinburgh, Institute of Genetic and Molecular Medicine and School of Veterinary Medicine, Edinburgh, EH4 2XR, United Kingdom.
700    1_
$a Clayton, John $u Mologic, Ltd, Bedford Technology Park, Thurleigh, Bedford, MK44 2YP, United Kingdom.
700    1_
$a Humphries, William $u Mologic, Ltd, Bedford Technology Park, Thurleigh, Bedford, MK44 2YP, United Kingdom.
700    1_
$a Hemmington, Sandra $u Mologic, Ltd, Bedford Technology Park, Thurleigh, Bedford, MK44 2YP, United Kingdom.
700    1_
$a Davis, Paul $u Mologic, Ltd, Bedford Technology Park, Thurleigh, Bedford, MK44 2YP, United Kingdom.
700    1_
$a Murray, Euan $u University of Edinburgh, Institute of Genetic and Molecular Medicine and School of Veterinary Medicine, Edinburgh, EH4 2XR, United Kingdom. INSERM Unité 940, Institut de Génétique Moléculaire, Université Paris 7, Hôpital St Louis, 27 rue Juliette Dodu, Paris, France.
700    1_
$a Limeneh, Asmare A $u Bahit Dar University College of Medicine and Health Sciences Department of Medical Biochemistry and Molecular Biology, Bahir Dar, Ethiopia.
700    1_
$a Ball, Kathryn $u University of Edinburgh, Institute of Genetic and Molecular Medicine and School of Veterinary Medicine, Edinburgh, EH4 2XR, United Kingdom.
700    1_
$a Ruckova, Eva $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
700    1_
$a Muller, Petr $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
700    1_
$a Vojtesek, Borek $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
700    1_
$a Fahraeus, Robin $u INSERM Unité 940, Institut de Génétique Moléculaire, Université Paris 7, Hôpital St Louis, 27 rue Juliette Dodu, Paris, France.
700    1_
$a Argyle, David $u University of Edinburgh, Institute of Genetic and Molecular Medicine and School of Veterinary Medicine, Edinburgh, EH4 2XR, United Kingdom. $7 gn_A_00008356
700    1_
$a Hupp, Ted R $u University of Edinburgh, Institute of Genetic and Molecular Medicine and School of Veterinary Medicine, Edinburgh, EH4 2XR, United Kingdom.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 11, č. 2 (2016), s. e0148366
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26894679 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20161005132630 $b ABA008
999    __
$a ok $b bmc $g 1165970 $s 952286
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 11 $c 2 $d e0148366 $e 20160219 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20161005

Find record

Citation metrics

Archiving options